Search results
Showing 1 to 15 of 8216 results
Details, meeting dates and minutes of the independent technology appraisal committees
Tools and resources to help you implement guidance and quality standards at work.
The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient
Resources to help with planning ahead for NICE guidance, understanding where you are now, and conducting improvement initiatives.
NICE is unable to make a recommendation about the use in the NHS of baricitinib (Olumiant) for treating juvenile idiopathic arthritis in people 2 years and over. This is because Eli Lilly did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA982
Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)
Evidence-based recommendations on voxelotor (Oxbryta) for haemolytic anaemia caused by sickle cell disease in people 12 years and over.
We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)
Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.
NICE is unable to make a recommendation on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over. This is because Bristol-Myers Squibb did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA980
We have updated our prioritisation process , and now use a consistent, common framework to inform all our prioritisation decisions. We strive to...
NICE is a great place to work. You'll be working alongside talented, friendly people on services that have a real impact on health and social care in...
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making